Edgewise Therapeutics, Inc. (EWTX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EWTX SEC filings page.
This page shows Edgewise Therapeutics, Inc. (EWTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Edgewise operates as a development-stage business: rising R&D drives losses, while external financing—not operations—funds cash needs.
The near match between FY2025’s operating loss and operating cash outflow indicates the reported losses are largely cash costs of development, not mainly accounting charges; FY2024 showed the same relationship even as the amounts increased.
R&D reached
Debt-to-equity was 0.1x in FY2025, pointing to a balance sheet funded far more by equity than borrowing. Financing cash flow of
Financial Health Signals
Edgewise Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Edgewise Therapeutics, Inc. passes 0 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Edgewise Therapeutics, Inc. reported a net loss of $168K while operations used $143.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Edgewise Therapeutics, Inc.'s EBITDA was -$61.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 45.9% from the same quarter a year earlier. Against the prior quarter it is down 14.7%.
Edgewise Therapeutics, Inc. reported -$57.3M in net income in Q2 2026. This represents a decrease of 58.7% from the same quarter a year earlier. Against the prior quarter it is down 17.0%.
Edgewise Therapeutics, Inc. earned -$0.53 per diluted share (EPS) in Q2 2026. This represents a decrease of 55.9% from the same quarter a year earlier. Against the prior quarter it is down 15.2%.
Not reported for Q2 2026.
Cash & Balance Sheet
Edgewise Therapeutics, Inc. recorded an outflow of $42.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 30.2% from the same quarter a year earlier. Against the prior quarter it is up 0.7%.
Edgewise Therapeutics, Inc. held $72.3M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Edgewise Therapeutics, Inc.'s ROE was -12.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 6.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.9 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Edgewise Therapeutics, Inc. invested $47.5M in research and development in Q2 2026. This represents an increase of 41.7% from the same quarter a year earlier. Against the prior quarter it is up 11.5%.
Edgewise Therapeutics, Inc. invested $32K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 36.0% from the same quarter a year earlier. Against the prior quarter it is down 87.7%.
Not reported for Q2 2026.
EWTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $47.5M+41.7% | $42.7M+16.0% | N/A | $37.5M+16.3% | $33.6M+9.4% | $36.8M+32.7% | N/A | $32.2M+35.5% |
| SG&A Expenses | $14.4M+59.0% | $11.5M+24.6% | N/A | $9.4M+14.2% | $9.1M+21.9% | $9.2M+30.4% | N/A | $8.2M+44.9% |
| Operating Income | -$61.9M-45.4% | -$54.1M-17.7% | N/A | -$46.9M-15.9% | -$42.6M-11.8% | -$46.0M-32.2% | N/A | -$40.4M-37.3% |
| EBITDA | -$61.4M-45.9% | -$53.5M-17.9% | N/A | -$46.3M-16.2% | -$42.1M-12.0% | -$45.4M-32.7% | N/A | -$39.9M-37.5% |
| Net Income | -$57.3M-58.7% | -$49.0M-20.1% | N/A | -$40.7M-19.2% | -$36.1M-14.7% | -$40.8M-43.0% | N/A | -$34.1M-32.7% |
| EPS (Basic) | -$0.53-55.9% | -$0.46-7.0% | -$0.48-14.3% | -$0.39-8.3% | -$0.340.0% | -$0.43-30.3% | -$0.42+10.6% | -$0.36+12.2% |
| EPS (Diluted) | -$0.53-55.9% | -$0.46-7.0% | -$0.48-14.3% | -$0.39-8.3% | -$0.340.0% | -$0.43-30.3% | -$0.42+10.6% | -$0.36 |
| Diluted Shares (Avg) | 108M+2.6% | 107M+12.6% | N/A | 105M+12.4% | 105M+12.2% | 95M+8.6% | N/A | 94M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
EWTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $479.7M-21.8% | $518.5M+14.1% | $552.6M+13.5% | $583.5M+14.1% | $613.3M+15.4% | $454.4M-18.0% | $486.8M+43.2% | $511.3M+64.2% |
| Current Assets | $471.5M-21.8% | $509.8M+15.0% | $543.4M+14.3% | $573.9M+14.9% | $603.3M+16.1% | $443.2M-18.1% | $475.5M+45.4% | $499.4M+67.6% |
| Cash & Equivalents | $72.3M+66.6% | $33.2M-33.5% | $61.1M+46.8% | $46.0M+2.7% | $43.4M-0.2% | $49.9M+65.0% | $41.7M-51.6% | $44.8M+36.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $31.6M+30.3% | $25.3M+2.6% | $30.3M+9.9% | $24.8M+10.8% | $24.3M+14.6% | $24.7M+30.8% | $27.6M+30.2% | $22.4M+7.0% |
| Current Liabilities | $29.0M+39.0% | $22.5M+6.8% | $27.4M+14.7% | $21.6M+14.2% | $20.9M+21.7% | $21.1M+44.6% | $23.9M+42.3% | $19.0M+16.0% |
| Non-Current Liabilities | $2.6M-23.7% | $2.8M-22.0% | $3.0M-20.4% | $3.2M-8.0% | $3.4M-15.8% | $3.6M-16.6% | $3.7M-15.6% | $3.4M-25.0% |
| Total Equity | $448.1M-23.9% | $493.2M+14.8% | $522.3M+13.7% | $558.6M+14.3% | $589.1M+15.4% | $429.7M-19.7% | $459.2M+44.0% | $488.9M+68.3% |
| Retained Earnings | -$652.7M-43.3% | -$595.4M-42.0% | -$546.4M-44.3% | -$496.2M-46.4% | -$455.5M-49.4% | -$419.4M-53.5% | -$378.6M-54.7% | -$338.9M-57.9% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
EWTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$42.5M-30.3% | -$42.5M-12.4% | -$38.6M-43.2% | -$34.8M-27.0% | -$32.6M-24.8% | -$37.9M-32.4% | -$27.0M-0.5% | -$27.4M-24.1% |
| Depreciation & Amortization | $556K+2.2% | $590K+6.5% | $575K-8.6% | $547K-2.8% | $544K-1.8% | $554K+5.5% | $629K+18.0% | $563K+25.7% |
| Stock-Based Compensation | $9.4M+21.1% | $8.7M-3.8% | N/A | $8.1M+17.5% | $7.7M+48.0% | $9.1M+86.0% | N/A | $6.9M+50.9% |
| Capital Expenditures | $32K-36.0% | $260K+490.9% | $73K-73.4% | $89K-82.9% | $50K-77.4% | $44K-85.2% | $274K+70.2% | $520K+13.8% |
| Free Cash Flow | -$42.5M-30.2% | -$42.8M-12.9% | -$38.7M-42.0% | -$34.9M-25.0% | -$32.6M-24.0% | -$37.9M-31.2% | -$27.2M-0.9% | -$27.9M-23.9% |
| Investing Cash Flow | $78.5M+148.4% | $2.4M-94.5% | $49.8M+137.8% | $35.7M+40.8% | -$162.2M-534.0% | $43.9M+116.4% | $20.9M-22.5% | $25.4M+8.3% |
| Financing Cash Flow | $3.1M-98.4% | $12.2M+447.6% | $4.0M+37.3% | $1.7M-50.2% | $188.2M+9543.0% | $2.2M-99.1% | $2.9M-94.5% | $3.3M+1679.6% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
EWTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -12.8%-6.7pp | -9.9%-0.5pp | N/A | -7.3%-0.3pp | -6.1%0.0pp | -9.5%-4.2pp | N/A | -7.0%+1.9pp |
| Return on Assets | -11.9%-6.1pp | -9.4%-0.5pp | N/A | -7.0%-0.3pp | -5.9%0.0pp | -9.0%-3.8pp | N/A | -6.7%+1.6pp |
| Current Ratio | 16.24-12.6x | 22.61+1.6x | 19.85-0.1x | 26.51+0.2x | 28.87-1.4x | 20.99-16.1x | 19.93+0.4x | 26.35+8.1x |
| Debt-to-Equity | 0.070.0x | 0.050.0x | 0.060.0x | 0.040.0x | 0.040.0x | 0.060.0x | 0.060.0x | 0.050.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Edgewise Therapeutics, Inc. EWTX | FY2025 | N/A | -$168K | N/A | $4.2B | — |
| Viridian Therapeutics, Inc. VRDN | FY2025 | $70.8M | -$342.6M | N/A | $2.1B | 67/100 |
| Vera Therapeutics, Inc. VERA | FY2025 | N/A | -$299.6M | N/A | $2.2B | — |
| Aurinia Pharmaceuticals Inc AUPH | FY2025 | $283.1M | $287.2M | N/A | $2.2B | 56/100 |
| Ardelyx, Inc. ARDX | FY2025 | $407.3M | -$62.0M | -15.2% | $846.9M | 45/100 |
| Pharvaris N.V. PHVS | FY2020 | N/A | -$26.0M | N/A | $2.2B | — |
Where Edgewise Therapeutics, Inc. Ranks
Frequently Asked Questions
Is Edgewise Therapeutics, Inc. profitable?
No, Edgewise Therapeutics, Inc. (EWTX) reported a net income of -$168K in fiscal year 2025.
What is Edgewise Therapeutics, Inc.'s EBITDA?
Edgewise Therapeutics, Inc. (EWTX) had EBITDA of -$189.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Edgewise Therapeutics, Inc.'s return on equity (ROE)?
Edgewise Therapeutics, Inc. (EWTX) has a return on equity of 0.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Edgewise Therapeutics, Inc.'s free cash flow?
Edgewise Therapeutics, Inc. (EWTX) recorded an outflow of $144.1M in free cash flow during fiscal year 2025. This represents a -30.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Edgewise Therapeutics, Inc.'s operating cash flow?
Edgewise Therapeutics, Inc. (EWTX) recorded an outflow of $143.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Edgewise Therapeutics, Inc.'s total assets?
Edgewise Therapeutics, Inc. (EWTX) had $552.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Edgewise Therapeutics, Inc.'s capital expenditures?
Edgewise Therapeutics, Inc. (EWTX) invested $256K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Edgewise Therapeutics, Inc. spend on research and development?
Edgewise Therapeutics, Inc. (EWTX) invested $151.4M in research and development during fiscal year 2025.
What is Edgewise Therapeutics, Inc.'s current ratio?
Edgewise Therapeutics, Inc. (EWTX) had a current ratio of 19.85 as of fiscal year 2025, which is generally considered healthy.
What is Edgewise Therapeutics, Inc.'s debt-to-equity ratio?
Edgewise Therapeutics, Inc. (EWTX) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Edgewise Therapeutics, Inc.'s return on assets (ROA)?
Edgewise Therapeutics, Inc. (EWTX) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Edgewise Therapeutics, Inc.'s P/E ratio?
Edgewise Therapeutics, Inc. (EWTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $4.2B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Edgewise Therapeutics, Inc.'s price-to-sales ratio?
Edgewise Therapeutics, Inc. (EWTX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $4.2B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Edgewise Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Edgewise Therapeutics, Inc. (EWTX) held $61.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $143.8M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Edgewise Therapeutics, Inc.'s Piotroski F-Score?
Edgewise Therapeutics, Inc. (EWTX) has a Piotroski F-Score of 0 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Edgewise Therapeutics, Inc.'s earnings high quality?
Edgewise Therapeutics, Inc. (EWTX) reported a net loss of $168K while operations used $143.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.